Literature DB >> 31091351

S100A8 acts as an autocrine priming signal for heme-induced human Mϕ pro-inflammatory responses in hemolytic inflammation.

Angélica A A Silveira1, Olwyn R Mahon2, Clare C Cunningham2, Emma M Corr2, Rafaela Mendonça1, Sara T O Saad1, Fernando F Costa1, Aisling Dunne2, Nicola Conran1.   

Abstract

Intravascular hemolysis, in addition to reducing red cell counts, incurs extensive vascular inflammation and oxidative stress. One product of hemolysis, heme, is a potent danger associated molecular pattern (DAMP), activating leukocytes and inducing cytokine expression and processing, among other pro-inflammatory effects. We explored pathways by which heme-induced inflammation may be amplified under sterile conditions. Incubation of human Mϕs, differentiated from CD14+ cells, with heme induced time- and concentration-dependent gene and protein expression of S100A8, a myeloid cell-derived alarmin. Human Mϕ stimulation with recombinant S100A8, in turn, induced robust pro-IL-1β expression that was dependent upon NF-κB activation, gene transcription, and partially dependent upon TLR4-mediated signaling. Moreover, heme itself stimulated significant Mϕ pro-IL-1β gene and protein expression via an S100A8-mediated mechanism and greatly amplified S100A8-driven NLRP3 inflammasome-mediated IL-1β secretion. In vivo, induction of acute intravascular hemolysis in mice induced a rapid elevation of plasma S100A8 that could be abolished by hemopexin, a heme scavenger. Finally, plasma S100A8 levels were found to be significantly elevated in patients with the inherited hemolytic anemia, sickle cell anemia, when compared with levels in healthy individuals. In conclusion, we demonstrate that hemolytic processes are associated with S100A8 generation and that some of the inflammatory effects of heme may be amplified by autocrine S100A8 production. Findings suggest a mechanism by which hemolytic inflammation could be propagated via leukocyte priming by endogenous proteins, even in sterile inflammatory environments such as those that occur in the hemolytic diseases. S100A8 may represent a therapeutic target for reducing inflammation in hemolytic disorders. ©2019 Society for Leukocyte Biology.

Entities:  

Keywords:  Mϕ; NF-κB; heme; hemolytic diseases; inflammasome; leukocytes; sickle cell disease; sterile inflammation

Year:  2019        PMID: 31091351     DOI: 10.1002/JLB.3MIA1118-418RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  4 in total

1.  S100A8 accelerates wound healing by promoting adipose stem cell proliferation and suppressing inflammation.

Authors:  WeiGuo Su; PingLi Wang; QiQiang Dong; ShengJun Li; ShuiWang Hu
Journal:  Regen Ther       Date:  2022-07-15       Impact factor: 3.651

Review 2.  Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit.

Authors:  Marie Frimat; Idris Boudhabhay; Lubka T Roumenina
Journal:  Toxins (Basel)       Date:  2019-11-13       Impact factor: 4.546

Review 3.  What Is Next in This "Age" of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron.

Authors:  Luis Montecinos; Jeffrey D Eskew; Ann Smith
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-24

Review 4.  Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology.

Authors:  Maria A Lizarralde-Iragorri; Arun S Shet
Journal:  Int J Mol Sci       Date:  2020-07-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.